|
- Annual Report 2023 - Octapharma AG
Octapharma remains firmly focused on the future, continuously pioneering in the field of bleeding management Fibrinogen, the first factor to be depleted in massive bleeding scenarios, typically seen in trauma and surgery, is one of our key areas of interest
- Package Insert - Octagam 10% liquid solution for intravenous . . .
These highlights do not include all the information needed to use Octagam 10% safely and effectively See full prescribing information for Octagam 10% Thrombosis may occur with immune globulin
- octaplex
The preparation complies with the monograph on Human Prothrombin Complex (freeze-dried) of the European Pharmacopoeia (2005:0554) octaplex® is a further development of "PPSB Prothrombinkomplex human 250 500", the previous generation of PCC marketed by Octapharma
- Page 1 of 3 Pages 2024 octagam 5% octagam 10% Copay . . .
2024 octagam® 5% octagam® 10% Copay Enrollment Form Please print and fax completed form to: 1-800-554-6744 If you have any questions please call the Octapharma Support Center toll free at 1-800-554-4440 | Monday to Friday 8:30 AM to 5 PM ET
- A Guide to Open Enrollment
g In Your Medical Benefits All employees eligible for medical benefits must take a ride through our Online Medical Benefits Center this year to enroll in their medical benef ts for the 2022 plan year To simplify your journey, we’ve given you some easy-to-follow
- Octagam 5% [Immune Globulin Intravenous (Human) Liquid . . .
Thrombosis may occur with immune globulin intravenous (IGIV) products, including Octagam 5% liquid Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors
- CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY . . .
Octanorm (also known as Cutaquig), the investigational product (IMP) in this study, is an immunoglobulin preparation from human normal plasma and is manufactured by Octapharma
|
|
|